WJ01024

Phase 1Small molecule

SSuzhou Junjing BioSciences Co., Ltd.

WJ01024 is one of 2 small molecule programs targeting Splenomegaly. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SplenomegalyRecruiting

SplenomegalyPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Splenomegaly

#DrugCompanyPhaseTrials

Ojjaara

GGlaxo Dba Glaxosmithkline

Approved

—2

WJ01024

SSuzhou Junjing BioSciences Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Splenomegaly

NCT07802405

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer

Terminated·SSuzhou Junjing BioSciences Co., Ltd.·Phase 1·NCT04991129·23 enrolled

Splenomegaly1 trial

A Phase I Clinical Study Evaluating the Safety and Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of Oral Administration of WJ01024 as a Monotherapy and in Combination With Ruxolitinib in Patients With Myelofibrosis

Recruiting·HHenan Cancer Hospital·Phase 1·NCT07802405·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for WJ01024. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — WJ01024 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for WJ01024. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Junjing BioSciences Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSuzhou Junjing BioSciences Co., Ltd.

WJ01024

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Safety and Efficacy1 trial

Splenomegaly1 trial

References

Drug Info

Quick Facts

Related News